CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod
CervoMed's stock surged 15% following FDA's orphan drug designation for neflamapimod, a frontotemporal dementia treatment. The company plans a proof-of-principle study and Phase 3 trial in mid-2025 for the rare disease affecting thousands worldwide.